This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients

Stocks in this article: INCY

NEW YORK (TheStreet) -- Incyte (INCY) has been a source of investor contention since the company first announced Jakafi was effective in increasing overall survival in pancreatic cancer patients. The controversy centered on Incyte's analysis, which found a survival benefit favoring Jakafi only in a subset of pancreatic cancer patients with elevated levels of C-reactive protein (CRP), a biomarker for inflammation.

At this year's American Society of Clinical Oncology (ASCO) annual meeting, Incyte addressed the Jakafi controversy. The company asserted the drug's mechanism of action -- the inhibition of the JAK 1/2 pathway -- is known to reduce inflammatory cytokines, which in turn, leads to a more robust anti-cancer response in patients. In addition, the presence of systemic inflammation in patients with advanced cancer is a negative prognostic factor, so if one could reduce that inflammation, survival would increase, the company said. 

To further explicate the biomarker analysis, the Jakafi ASCO presentation described a well-established clinical measure of inflammation called the modified Glasgow Prognostic Score (mGPS) which look at levels of CRP and albumin. For mGPS, patients with CRP below 10 mg/L have the best prognosis and are scored 0. Patients with CRP greater than 10 mg/L and albumin greater than 35 g/L are slightly worse and scored 1; those with CRP greater than 10 mg/L and albumin less than 35 g/L have the worst prognosis and are scored 2. This measure has been used in over 50 clinical studies that have independently validated its utility as a prognostic indicator across a range of tumor types.

Having a validated scale correlated with survival adds a level of comfort to the Jafaki pancreatic cancer subset analysis, with one caveat: Incyte examined the effect of Jakafi on patients with CRP above 13 mg/L, a different level than what's defined in the mGPS. Moreover, Incyte disregards albumin levels in its analysis.

Putting aside the question of the CRP cut-off, in pancreatic cancer patients with CRP levels above 13 mg/L, the addition of Jakafi lead to a statistically significant overall survival benefit, says Incyte. (OS hazard ratio was 0.47 with a p-value of 0.01.) Oddly, the progression-free survival benefit in this patient subset was not statistically significant. (PFS hazard ratio of 0.62 and p-value of 0.10.)

Incyte also analyzed the Jakafi pancreatic cancer data to parse the overall survival benefit based on mGPS-defined scores of 0, 1, 2, and those patients scored 1 or 2. These analyses provide a hint of what would happen to the Jakafi results with slight changes in the CRP cut-offs. Similar results would bolster confidence in Incyte's method of defining the subset of pancreatic patients benefiting from Jakafi.

There was no statistically significant overall survival benefit in any of the mGPS groups, although survival time trended higher with lower inflammation. This finding doesn't necessarily invalidate Incyte's use of a 13 mg/L CRP cut off but confidence in the analysis should be lessened. Incyte is conducting a phase III study of Jakafi in pancreatic cancer, recruiting patients based on mGPS. The uncertain survival finding from the phase II study based on the mGPS analysis is concerning. 

Treating pancreatic cancer patients with Jakafi might have a minor benefit, but the totality of the results in the phase II trial do not inspire high confidence in the phase III program.

Sobek has no position in Incyte.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,719.00 +33.27 0.19%
S&P 500 2,052.75 +4.03 0.20%
NASDAQ 4,701.8670 +26.1550 0.56%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs